drugset / Trial / NCT01591447

Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

NCT01591447

Phase 2 Completed 60 enrolled Melinta Therapeutics, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of a single dose of solithromycin (CEM-101) for the treatment of uncomplicated urogenital gonorrhea.

Timeline

Start
2012-05
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Solithromycin Other / unclassified 1000 mg Oral
Subject Solithromycin Other / unclassified 1200 mg Oral

Indications